Brepocitinib’s expansion into LPP adds meaningful optionality ahead of the Q3 2026 PDUFA decision for dermatomyositis. Traders should monitor for upcoming Phase 3 data in uveitis and enrollment progress in LPP, which could drive further upside. The lack of current treatments and strong mechanistic rationale increases the likelihood of accelerated development and commercial success.
Price Chart
Executive Summary
Roivant Sciences' subsidiary Priovant has initiated a seamless Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), a rare inflammatory scalp disorder with no FDA-approved treatments. This expands brepocitinib’s late-stage pipeline to four indications, with an NDA under Priority Review for dermatomyositis and a PDUFA date in Q3 2026. The program strengthens Roivant’s positioning in rare rheum-derm diseases.
Key Facts
- Priovant (a Roivant company) launched a seamless Phase 2b/3 trial for brepocitinib in lichen planopilaris (LPP), enrolling first patients in March 2026.
- LPP is a rare, scarring hair loss condition affecting ~100,000 adults in the U.S. with no FDA-approved therapies.
- Brepocitinib is a first-in-class dual JAK1/TYK2 inhibitor with potential in multiple autoimmune orphan diseases.
- FDA has granted Priority Review for brepocitinib’s NDA in dermatomyositis, with a PDUFA date in Q3 2026.
- Phase 3 data in non-infectious uveitis expected in H2 2026; Phase 3 in cutaneous sarcoidosis to start same period.
Financial Impact
High-value orphan drug expansion: brepocitinib now in four late-stage indications, with dermatomyositis near approval and LPP addressing a $500M+ peak sales opportunity based on prevalence and unmet need.
Risk Factors
- Clinical trial failure risk in LPP or other indications.
- Regulatory delay or rejection of NDA for dermatomyositis despite Priority Review.
- Competition from emerging JAK/TYK2 inhibitors in autoimmune space.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267158 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $36.80 | awaiting T+20 | — | $36.05 (−2.04%) |
Oct 5, 2026 21d ago | Insider Cluster | $35.53 | awaiting T+20 | — | $36.05 (−1.46%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 17, 2026 5w ago | Insider Cluster | $39.77 $33.53 | ▼ −15.69% | ▼ −15.89% | $36.05 (−9.35%) |
Sep 1, 2026 7w ago | Insider Cluster | $34.18 $36.57 | ▲ +6.99% | ▲ +7.32% | $36.05 (+5.47%) |
Aug 27, 2026 8w ago | Press Release | $37.58 $36.13 | ▼ −3.86% | ▼ −3.35% | $36.05 (−4.07%) |
Aug 27, 2026 8w ago | Press Release | $37.58 $36.13 | ▼ −3.86% | ▼ −3.35% | $36.05 (−4.07%) |
Aug 26, 2026 8w ago | Press Release | $36.75 $38.99 | ▲ +6.10% | ▲ +4.89% | $36.05 (−1.90%) |
Aug 6, 2026 11w ago | 8-K | $35.12 $34.41 | ▼ −2.02% | ▼ −2.62% | $36.05 (+2.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers